Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:
“4 year update of checkmate 743: Nivo-ipi continues to outperform pemetrexed-platinum chemo in malignant mesothelioma.
Significant benefit in non-epithelioid histology (HR 0.48).”
